Skip to main content
Top
Published in: Clinical and Experimental Medicine 4/2019

01-11-2019 | Hypersensitivity Pneumonitis | Original Article

NK and NKT-like cells in granulomatous and fibrotic lung diseases

Authors: L Bergantini, P Cameli, M d’Alessandro, C Vagaggini, RM Refini, C Landi, MG Pieroni, M Spalletti, P Sestini, E Bargagli

Published in: Clinical and Experimental Medicine | Issue 4/2019

Login to get access

Abtract

Background The pathogenetic and regulatory roles of natural killer (NK) and natural killer T-like cells in interstitial lung diseases (ILDs), fibrotic and granulomatous of unknown etiology are unclear. Objectives Here we investigated NK and NKT-like cells in peripheral blood (PB) and Bronchoalveolar lavage (BAL) from patients with ILDs. Method 190 patients (94 male mean age 61 ± 14.3 years) and 8 controls undergoing bronchoscopy for ILD diagnostic work-up were enrolled consecutively; 115 patients sarcoidosis, 24 chronic fibrotic hypersensitivity pneumonitis and 43 patients other ILDs [32 idiopathic pulmonary fibrosis (IPF) and 11 non-specific interstitial pneumonia (NSIP)]. PB and BAL were processed by flow cytometry using monoclonal antibodies to differentiate NK and NKT-like cells. Results NK% in BAL was significantly different among ILDs (p = 0.02). Lower NK% was observed in BAL from sarcoidosis than other ILDs (p < 0.05). Similar findings were observed for NKT-like, whereas no differences were found for PB NK%. Difference of NK% was observed between BAL and PB in all groups (p < 0.001). Sarcoidosis patients reported the best area under the curve for NKT-like (AUC = 0.678, p = 0.0015) and NK cells (AUC = 0.61, p = 0.001). In the IPF-NSIP subgroup, NK% cell was inversely correlated with FVC% (r = − 0.34, p = 0.03) and DLCO% (r = − 0.47, p = 0.0044). Conclusions NK and NKT-like were expressed differently in BAL from patients with different ILD and were significantly depleted in sarcoidosis respect to other ILDs. This suggests that these cells may play a protective role in the pathogenesis of sarcoidosis.
Appendix
Available only for authorised users
Literature
18.
go back to reference Souza-Fonseca-Guimaraes P, Guimaraes F, Natânia De Souza-Araujo C, et al. Natural killer cell assessment in peripheral circulation and bronchoalveolar lavage fluid of patients with severe sepsis: a case control study. Int J Mol Sci. 2017;18(3):1–2. https://doi.org/10.3390/ijms18030616.CrossRef Souza-Fonseca-Guimaraes P, Guimaraes F, Natânia De Souza-Araujo C, et al. Natural killer cell assessment in peripheral circulation and bronchoalveolar lavage fluid of patients with severe sepsis: a case control study. Int J Mol Sci. 2017;18(3):1–2. https://​doi.​org/​10.​3390/​ijms18030616.CrossRef
24.
go back to reference Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/World association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 1999;16(2):149–73. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/World association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 1999;16(2):149–73.
32.
go back to reference Agostini C, Trentin L, Zambello R, et al. Phenotypical and functional analysis of natural killer cells in sarcoidosis. Clin Immunol Immunopathol. 1985;37(2):262–75.CrossRefPubMed Agostini C, Trentin L, Zambello R, et al. Phenotypical and functional analysis of natural killer cells in sarcoidosis. Clin Immunol Immunopathol. 1985;37(2):262–75.CrossRefPubMed
Metadata
Title
NK and NKT-like cells in granulomatous and fibrotic lung diseases
Authors
L Bergantini
P Cameli
M d’Alessandro
C Vagaggini
RM Refini
C Landi
MG Pieroni
M Spalletti
P Sestini
E Bargagli
Publication date
01-11-2019
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 4/2019
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-019-00578-3

Other articles of this Issue 4/2019

Clinical and Experimental Medicine 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine